Andere Sprachen NRx Pharmaceuticals, Inc.

Aktien

A4091K

US6294442099

BRPA

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:42:17 29.04.2024			% 5 Tage	% 1. Jan.
3,525 ^USD	-0,42 %		+21,66 %	-20,66 %

18.04.	Exchange-Traded Funds und Aktienfutures steigen am Donnerstag vor den Reden der Fed-Politiker	MT
17.04.	NRx Pharmaceuticals, Inc. Neue Daten zu NRX-101 zeigen keine Schädigung der Darm- und Vaginalflora in validierten Nagetiermodellen im Vergleich zu Standardantibiotika	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock	19.04.
NRx Pharmaceuticals Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement	19.04.
NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	18.04.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	18.04.
Top Premarket Decliners	18.04.
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket	18.04.
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital	17.04.
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics	17.04.
NRx Pharmaceuticals Announces Development of New, Proprietary Formulation of HTX-100	16.04.
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)	15.04.
NRx Pharmaceuticals Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	09.04.
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	08.04.
NRx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	02.04.
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.03.
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights	28.03.
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	28.03.
UPDATE, NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	27.03.
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024	26.03.
NRx Pharmaceutical's Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK	26.03.
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK	25.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NRx Pharmaceuticals, Inc.

Aktien

A4091K

US6294442099

BRPA

Andere Sprachen

Filter